Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster
Colorado
80020
United States
Tel: 303-426-6262
Fax: 303-426-4731
Website: http://www.allos.com/
Email: corpcomm@allos.com
210 articles about Allos Therapeutics, Inc.
-
Allos Therapeutics, Inc. To Present At Upcoming Investor Conferences
8/29/2006
-
Allos Therapeutics, Inc. Initiates Pivotal Phase 2 Study Of PDX In Patients With Peripheral T-Cell Lymphoma
8/29/2006
-
Allos Therapeutics, Inc. Reports Second Quarter 2006 Financial Results
8/7/2006
-
Allos Therapeutics, Inc. Receives Special Protocol Assessment For Pivotal Phase 2 Study Of The Company's Novel Antifolate PDX In Patients With Peripheral T-Cell Lymphoma
8/2/2006
-
FDA Grants Orphan Drug Designation To Allos Therapeutics, Inc.'s Novel Antifolate PDX For The Treatment of T-Cell Lymphoma
7/26/2006
-
The Day In Review: Biotech 4.5% Higher In 3 Days
7/25/2006
-
Allos Therapeutics, Inc. Files Shelf Registration Statement
6/13/2006
-
Allos Therapeutics, Inc. To Present At The 2006 Needham & Company Biotechnology Conference
6/7/2006
-
Allos Therapeutics, Inc. Appoints James V. Caruso As Chief Commercial Officer
6/6/2006
-
Allos Therapeutics, Inc.' EFAPROXYN(TM) Found To Reduce Tumor Hypoxia And HIF-1-alpha Expression In Human Breast Cancer Xenografts
6/5/2006
-
Allos Therapeutics, Inc. Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350
5/26/2006
-
Allos Therapeutics, Inc. Reports First Quarter 2006 Financial Results
5/9/2006
-
Interim Analysis Supports Continuation Of Allos Therapeutics, Inc.'s Pivotal Phase 3 Trial
4/4/2006
-
Allos Therapeutics, Inc. Names Chief Executive Offficer
3/10/2006
-
Allos Therapeutics, Inc. Reports 2005 Financial Results
3/6/2006
-
Allos Therapeutics, Inc. To Present At The 2006 SG Cowen & Co., LLC Healthcare Conference
3/1/2006
-
Scheduled Combination Of Allos Therapeutics, Inc.' Pralatrexate Plus Gemcitabine Proves Superior To Methotrexate Plus Cytarabine In Models Of Human Non-Hodgkin's Lymphoma
2/14/2006
-
Allos Therapeutics, Inc. To Present At The 2006 Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/1/2006
-
Allos Therapeutics, Inc. Announces CEO Succession Plans
1/17/2006
-
Allos Therapeutics, Inc. Release: Results Published In Journal Of Clinical Oncology Affirm Survival Benefit Of EFAPROXYN(TM) In Patients With Brain Metastases Originating From Breast Cancer
1/3/2006